Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: A comparative study with clinically used platinum derivatives

Cancer Science

Volumn 101, Issue 11, 2010, Pages 2476-2482

  Feng, Zhen ^a   Lai, Yuping ^a   Ye, Haifeng ^a   Huang, Jing ^a   Xi, Xu Guang ^b   Wu, Zirong ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; DRUG CARRIER; OXALIPLATIN; POLY (GAMMA, L GLUTAMIC ACID) CISPLATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG SENSITIVITY; FEMALE; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BODY WEIGHT; BREAST NEOPLASMS; CARBOPLATIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; FEMALE; FLOW CYTOMETRY; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; POLYGLUTAMIC ACID; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958615254     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01708.x     Document Type: Article

References (21)

1. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003; 10: 1663-82.
2. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009; 8: 10-6.
3. Arafa HM. Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids. Toxicology 2008; 254: 51-60.
4. Kraus KS, Ding D, Zhou Y, Salvi RJ. Central auditory plasticity after carboplatin-induced unilateral inner ear damage in the chinchilla: up-regulation of GAP-43 in the ventral cochlear nucleus. Hear Res 2009; 255: 33-43.
5. Reck M, Macha HN, Del Barco S et al. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer 2009; 64: 319-25.
6. Igawa S, Murakami H, Takahashi T et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2010; 67: 194-7.
7. Jerremalm E, Wallin I, Ehrsson H. New insights into the biotransfor-mation and pharmacokinetics of oxaliplatin. J Pharm Sci 2009; 98: 3879-85.
8. Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008; 29: 1100-6.
9. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008; 34: 368-77.
10. Capdevila J, Elez E, Peralta S, Macarulla T, Ramos FJ, Tabernero J. Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Rev Anticancer Ther 2008; 8: 1223-36.
11. Kim WJ, Kang MS, Kim HK et al. Water-soluble porphyrin-polyethylene glycol conjugates with enhanced cellular uptake for photodynamic therapy. J Nanosci Nanotechnol 2009; 9: 7130-5.
12. Chen H, Wang L, Yeh J et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials 2010; 31: 5397-407.
13. Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95: 4607-12.
14. Ye H, Jin L, Hu R et al. Poly(gamma, L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 2006; 27: 5958-65.
15. Hu R, Ye H, Jin L, Wu C, Wu Z. Screening and optimizing fermentation condition of Bacillus strain with high-productive poly-gamma-glutamic acid. China Biotechnology 2005; 25: 62-5.
16. Hanada K, Nagai N, Ogata H. Quantitative determination of unchanged cisplatin in rat kidney and liver by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 663: 181-6.
17. Augey V, Cociglio M, Galtier M, Yearoo R, Pinsani V, Bressolle F. High-performance liquid chromatographic determination of cis-dichloro-diammineplatinum(II) in plasma ultrafiltrate. J Pharm Biomed Anal 1995; 13: 1173-8.
18. Noguchi Y, Wu J, Duncan R et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998; 89: 307-14.
19. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006; 98: 335-44.
20. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J Control Release 1998; 53: 49-67.
21. Avichezer D, Schechter B, Arnon R. Functional polymers in drug delivery: carrier-supported CDDP (cis-platin) complexes of polycarboxylates - effect on human ovarian carcinoma. React Funct Polym 1998; 36: 59-69.